EVAX

Evaxion A/SA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$7.50

+111.9% vs current

Most likely

Base case

45%

Probability

Target price

$4.60

+29.9% vs current

B-

Bear case

30%

Probability

Target price

$2.20

-37.9% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Cautiously positive but still low-conviction. The deterministic prior leans positive, yet evidence quality is only 0.08 and uncertainty is 0.876, so the thesis is still mostly a monitored milestone setup rather than a strong fundamental call. The April 7 primary update improved visibility on EVX-01 timing, but funding and partnership execution still matter almost as much as the science.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystH1 2026 EVX-01 biomarker and immunogenicity updateHigh impact

Management said additional EVX-01 biomarker and immunogenicity findings are planned for H1 2026, giving the stock a near-term data checkpoint beyond the already reported two-year phase 2 signal [#PR-2026-03-05].

2026-09-30eventH2 2026 three-year EVX-01 phase 2 data after extension completionHigh impact

On April 7, 2026, Evaxion said the last patient completed the one-year extension of the EVX-01 phase 2 trial and that three-year clinical efficacy data are expected in the second half of 2026; that is the clearest stock-moving proof point for whether durability holds beyond the earlier two-year dataset [#PR-2026-04-07].

2026-11-30eventEVX-04 phase 1 regulatory filing target by year-end 2026High impact

The March 5, 2026 business update said EVX-04 is being prepared for a phase 1 trial and that regulatory filing is expected before the end of 2026, creating a second pipeline execution checkpoint beyond EVX-01 [#PR-2026-03-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology